Member log in

Pacific Edge widens first-half loss as US rollout gathers pace

Pacific Edge, which is banking on successfully commercialising its Cxbladder urine testing product, widened its first-half loss as it ramps up spending to set up its business in the US.

The Dunedin-based company made a loss of $3.2 million, or 1.2 cents per share, in the six months ended September 30, from $1.7 million, or 0.9 cents, a year earlier, it says in a statement.

Revenue climbed 29% to $325,000, though just $11,000 of that came from external customers.

"The majority of this net loss is the investment in the company's setting up of business in the US, clinical trials, product development and intellectual property as it is expensed," it says.

"The company is investing significant funds in the set-up and running of the commercial laboratory and the development of the US strategy in this financial year."

The shares fell 2.2% to 44 cents, having surged 137% this year. That values the company at $122.7 million.

Pacific Edge hopes to successfully bring its urine sampling system to market, having won clinical confirmation the Cxbladder is at least as effective as other methods from the American Journal of Urology.

The local company says that could be worth up to $100 million in five years.

Last month, the company completed its US lab in Pennsylvania and is waiting on regulatory approval to use the building.


Comments and questions

Same old same old story - losses and little revenue - $11,000???
Tears to come for investors.

I would check my facts if I were you as to where the company is in terms of its commercialisation phase and actual revenues.

Yep, tears of joy. Can't wait.

I'm thinking you didn't buy Diligent shares at 10c each, either. While PEB is not assured of success and, indeed, commercialisation may yet be challenging, I don't think it's science can now be faulted. Capital markets are to foster good ideas like these. The Americans understand these concepts and encourage them, with many failures and some spectacular successes resulting in a vibrant market where risk can be diversified, unlike the shallow pool here.

Dear Anonymous. You can check the credendials of the company's advisory boards here:
(page 4). Perhaps you might even like to compare them with your own.